Clinical trials: Metastases to Bone
Bone Metastases
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone metastases in subjects with advanced breast cancer.
- Trial name
- NCT00321464
- Testing
- Denosumab, Zoledronic Acid
- Volunteers
- 2,049 people
- Sponsor
- Amgen
Cancer, Hematologic Malignancies
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone disease from multiple myeloma.
- Conditions
- Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology
- Trial name
- NCT01345019
- Testing
- Denosumab, Zoledronic acid, Denosumab (for the open-label treatment phase)
- Where
- 309 sites in United States, Australia and 27 more
- Volunteers
- 1,718 people
- Sponsor
- Amgen
Bone Metastases
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases (lytic bone lesions from multiple myeloma) in subjects with advanced cancer and multiple…
- Trial name
- NCT00330759
- Testing
- Denosumab, Zoledronic Acid
- Volunteers
- 1,779 people
- Sponsor
- Amgen
Bone Metastases From Solid Tumors
Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors
This is a multicenter，randomized, double-blind, active-controlled, parallel-group study comparing efficacy and safety of LY01011 (recombinant anti-RANKL human monoclonal antibody injection) and Xgeva® in patients with bone…
- Trial name
- NCT04859569
- Testing
- LY01011, Xgeva®
- Where
- China
- Volunteers
- 850 people
- Sponsor
- Luye Pharma Group Ltd.
Pathological Fracture of Hip, Bone Metastases
Evaluation of the Performance of Y-STRUT® Medical Device to Strengthen Pre-fractural Tumour-induced Lesions at the Level of the Proximal Femur
HIPPON 100 is a national, multicentre, prospective, retrospective, descriptive and non-interventional study, in patients having a Y-STRUT® medical device implanted to prevent a high risk of impending pathological fracture.
- Trial name
- NCT03579212
- Testing
- Y-STRUT® (Hyprevention, Pessac, France)
- Where
- 4 sites in France
- Volunteers
- 16 people
- Sponsor
- Hyprevention
Neoplasms, Bone Metastases
Open Label Extension In Cancer Patients
To evaluate the safety and efficacy of anti-NGF AB in cancer patients with pain due to bone metastases who participated in the double-blind Study A4091003 and who wish to receive open-label therapy.
- Trial name
- NCT00830180
- Testing
- Anti-NGF AB
- Where
- 23 sites in United States, Austria and 8 more
- Volunteers
- 41 people
- Sponsor
- Pfizer
Prostate Cancer, Bone Metastases
A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases
- Trial name
- NCT00757757
- Testing
- MCS110
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Bone Metastases
To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors
A multi-center, randomized, double-blind, comparative study to evaluate the clinical efficacy and safety of QL1206 and Xgeva® in patients with bone metastases from solid tumors.
- Trial name
- NCT04550949
- Testing
- QL1206, Xgeva
- Where
- 2 sites in China
- Volunteers
- 700 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Breast Cancer, Prostate Cancer
Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate Cancer
Evaluation of patient reported outcomes (PRO) / QoL regarding typical ailments in real-life patients with bone metastases treated with osteoprotective agents.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Metastases
- Trial name
- PROBone (NCT02410044)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- iOMEDICO AG
Bone Metastases
ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain
A study to evaluate the safety and initial effectiveness of the ExAblate 2100 Conformal Bone System in the treatment of pain resulting from metastatic bone tumors.
- Trial name
- NCT00981578
- Testing
- ExAblate 2100
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- InSightec
Bone Metastases, Multiple Myeloma
ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone and Multiple Myeloma Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
- Trial name
- NCT00656305
- Testing
- ExAblate MRfFUS
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 147 people
- Sponsor
- InSightec
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
This trial will facilitate access to denosumab for adults with advanced cancer who have participated in a denosumab phase 3 study until denosumab is approved and available for sale.
- Trial name
- NCT01419717
- Testing
- Denosumab
- Where
- 64 sites in Argentina, Austria and 17 more
- Volunteers
- 129 people
- Sponsor
- Amgen
Bone Cancer, Bone Metastases
Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma
The goal of this study is to collect comparative data on safety and efficacy of MR Guided Focused Ultrasound and External Beam Radiation for treatment of metastatic bone tumors or multiple myeloma.
- Conditions
- Bone Cancer, Bone Metastases, Pain
- Trial name
- NCT01091883
- Testing
- Exablate treatment, Radiation
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- InSightec
Pain Resulting From Bone Metastases
ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
The purpose of this enhanced surveillance study ("ESS") is to collect information regarding chronic adverse events that are possibly related to the ExAblate® System ("ExAblate") that are received by InSightec ("InSightec")…
- Trial name
- BM019-Registry (NCT01834937)
- Testing
- ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- InSightec
Bone Metastases
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer
- Trial name
- NCT00321620
- Testing
- zoledronic acid, denosumab
- Volunteers
- 1,904 people
- Sponsor
- Amgen
Bone Metastases
Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors
JMT103 is a novel, full human IgG4 monoclonal antibody targeting RANKL. In preclinical studies, JMT103 demonstrated strong activity through blocking RANKL receptor, RANK on the surface of osteoclasts, leading to inhibit…
- Trial name
- JMT103 (NCT03550508)
- Testing
- Anti-RANKL Monoclonal Antibody
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai JMT-Bio Inc.
Bone Metastases
MR Guided Focused Ultrasound Surgery in the Treatment of Pain From Bone Tumors w/ the ExAblate 2000 Strappable System
A Feasibility Study To Evaluate the Safety and initial Effectiveness of MR guided Focused Ultrasound Surgery in the Treatment of pain resulting from Metastatic Bone Tumors with the ExAblate 2000 strappable system.
- Trial name
- BM005 (NCT03547557)
- Testing
- Exablate 2000 strappable system
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- InSightec
Bone Metastases
First-In Man (FIM) Study MR-Linac
Investigational device is the Magnetic resonance imager linear accelerator. Five (5) patients with bone metastases will be treated with palliative intention in this study.
- Trial name
- FIM MR-Linac (NCT03284619)
- Testing
- Magnetic resonance imager linear accelerator
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Nucletron Operations BV
Prostate Cancer, Bone Metastases
A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer
This study is intended to test an experimental new drug called, EMD 525797 (Study Drug). This drug is not yet approved for sale and has only been tested in a small number of people to date (prior to this study starting another…
- Trial name
- NCT00958477
- Testing
- EMD 525797
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 26 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Painful Bone Metastases, Breast Carcinoma
MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases
This study will evaluate treatment with High Intensity Focused Ultrasound (HIFU)in combination with ThermoDox (liposomal doxorubicin) is safe and effective in reducing pain for patients with painful bone metastases.
- Conditions
- Painful Bone Metastases, Breast Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT01640847
- Testing
- High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox
- Sponsor
- Imunon